نتایج جستجو برای: kinase inhibitors

تعداد نتایج: 385681  

Journal: :ImmunoHorizons 2021

Abstract Tyrosine kinase 2 (TYK2) is a member of the JAK family nonreceptor tyrosine kinase, together with JAK1, JAK2, and JAK3. JAKs are important signaling mediators many proinflammatory cytokines represent compelling pharmacological targets for autoimmune inflammatory diseases. Pan-acting small-molecule inhibitors were approved treatment rheumatoid arthritis ulcerative colitis. However, thei...

Journal: :Neuron 2001
Chih-Hung Lin Shiu-Hwa Yeh Chia-Ho Lin Kwok-Tung Lu Tzeng-Horng Leu Wen-Chang Chang Po-Wu Gean

Western blot analysis of neuronal tissues taken from fear-conditioned rats showed a selective activation of phosphatidylinositol 3-kinase (PI-3 kinase) in the amygdala. PI-3 kinase was also activated in response to long-term potentiation (LTP)-inducing tetanic stimulation. PI-3 kinase inhibitors blocked tetanus-induced LTP as well as PI-3 kinase activation. In parallel, these inhibitors interfe...

Journal: :Journal of onco-nephrology 2021

Hyponatremia is the most common electrolyte disorder in patients with cancer and associated significant morbidity mortality. Innovation therapies has led to substantial improvement outcomes, but also new therapy-related toxicities, including disturbance. Improvement clinicians understanding of hyponatremia may mitigate adverse outcomes improve quality life patients. In this case-illustrated rev...

Journal: :npj precision oncology 2021

Abstract Glucocorticoids, such as dexamethasone and prednisolone, are widely used in cancer treatment. Different hematological malignancies respond differently to this treatment which, could be expected, correlates with outcome. In study, we have a glucocorticoid-induced gene signature develop deep learning model that can predict sensitivity. By combining expression data from cell lines patient...

Journal: :Pharmacology & therapeutics 2015
Peng Wu Mads H Clausen Thomas E Nielsen

Small-molecule kinase inhibitors are invaluable targeted therapeutics for the treatment of various human diseases, especially cancers. While the majority of approved and developed preclinical small-molecule inhibitors are characterized as type I or type II inhibitors that target the ATP-binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets renders the ...

2012
Iakov N Rudenko Ruth Chia Mark R Cookson

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD. The LRRK2 protein contains a central catalytic region, and pathogenic mutations cluster in the Ras of complex protein C terminus of Ras of complex protein (mutations N1437H, R1441G/C and Y1699C) and kina...

Journal: :Cancer discovery 2013
Erick J Morris Sharda Jha Clifford R Restaino Priya Dayananth Hugh Zhu Alan Cooper Donna Carr Yongi Deng Weihong Jin Stuart Black Brian Long Jenny Liu Edward Dinunzio William Windsor Rumin Zhang Shuxia Zhao Minilik H Angagaw Elaine M Pinheiro Jagdish Desai Li Xiao Gerald Shipps Alan Hruza James Wang Joe Kelly Sunil Paliwal Xiaolei Gao Boga Sobhana Babu Liang Zhu Pierre Daublain Ling Zhang Bart A Lutterbach Marc R Pelletier Ulrike Philippar Phieng Siliphaivanh David Witter Paul Kirschmeier W Robert Bishop Daniel Hicklin D Gary Gilliland Lata Jayaraman Leigh Zawel Stephen Fawell Ahmed A Samatar

The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients with melanoma. However, the majority of responses are transient, and resistance is often associated with pathway reactivation of the extracellular ...

2012
Narender Singh Hongmao Sun Sidhartha Chaudhury Mohamed Diwan M. AbdulHameed Anders Wallqvist Gregory J. Tawa

BACKGROUND The current chemical space of known small molecules is estimated to exceed 1060 structures. Though the largest physical compound repositories contain only a few tens of millions of unique compounds, virtual screening of databases of this size is still difficult. In recent years, the application of physicochemical descriptor-based profiling, such as Lipinski's rule-of-five for drug-li...

2014
Yaoyu Chen Shaoguang Li

In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called homoharringtonine) is a natural alkaloid that inhibits protein synthesis and induces cell death. Om...

Journal: :Journal of chemical biology 2008
Lisa M Ballou Richard Z Lin

Mammalian target of rapamycin (mTOR) is a protein kinase that controls cell growth, proliferation, and survival. mTOR signaling is often upregulated in cancer and there is great interest in developing drugs that target this enzyme. Rapamycin and its analogs bind to a domain separate from the catalytic site to block a subset of mTOR functions. These drugs are extremely selective for mTOR and are...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید